Biopharmaceutical company Kintara Therapeutics Inc (Nasdaq: KTRA) announced on Monday that it has commenced a 15-patient clinical trial for REM-001 in cutaneous metastatic breast cancer (CMBC) patients.
The study aims to confirm the planned dose and optimise the trial design, paving the way for a Phase 3 clinical trial initiation.
REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, will be evaluated for its efficacy, with the primary endpoint being the Best Overall Objective Response Rate (bORR).
Kintara's dedication to developing novel cancer therapies aligns with its REM-001 Therapy program, addressing unmet medical needs in patients.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member